Azurity Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AZURITY, and when can generic versions of AZURITY drugs launch?
AZURITY has twenty-two approved drugs.
There are seventy-two US patents protecting AZURITY drugs.
There are three hundred and thirty-three patent family members on AZURITY drugs in forty-eight countries and forty supplementary protection certificates in fifteen countries.
Summary for Azurity
| International Patents: | 333 |
| US Patents: | 72 |
| Tradenames: | 22 |
| Ingredients: | 21 |
| NDAs: | 22 |
| Patent Litigation for Azurity: | See patent lawsuits for Azurity |
Drugs and US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | EPRONTIA | topiramate | SOLUTION;ORAL | 214679-001 | Nov 5, 2021 | RX | Yes | Yes | 11,633,374 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Azurity | E.E.S. | erythromycin ethylsuccinate | GRANULE;ORAL | 050207-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | FLEQSUVY | baclofen | SUSPENSION;ORAL | 215602-001 | Feb 4, 2022 | AB | RX | Yes | Yes | 11,446,246 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | 8,048,917 | ⤷ Try a Trial |
| Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | 8,048,917 | ⤷ Try a Trial |
| Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | 5,583,141 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
International Patents for Azurity Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | E031550 | ⤷ Try a Trial |
| Norway | 20083956 | ⤷ Try a Trial |
| Serbia | 50537 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Azurity Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1003503 | 05C0048 | France | ⤷ Try a Trial | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
| 1718641 | C20120005 00053 | Estonia | ⤷ Try a Trial | PRODUCT NAME: IPREZIV - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9281 FINAL 07.12.2011 |
| 0984957 | SPC/GB11/013 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
